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Abstract
Background: Hyperreflective foci have been described in OCT imaging of patients with retinal vascular diseases. It
has been suggested that they may play a role as a prognostic factor of visual outcomes in these diseases. The
purpose of this study is to describe the presence of hyperreflective foci in patients with non-infectious uveitic
macular edema and evaluate their behavior after treatment.
Methods: We conducted a multicenter, prospective, observational, 12-month follow-up study. Inclusion criteria
were age > 18 years and a diagnosis of non-infectious uveitic macular edema, defined as central macular thickness
of > 300 μm as measured by OCT and fluid in the macula. Collected data included best corrected visual acuity,
central macular thickness and the presence, number and distribution (inner or outer retinal layers) of hyperreflective
foci. Evaluations were performed at baseline, and at 1, 3, 6, and 12 months after starting treatment.
Results: We included 24 eyes of 24 patients. The frequency of patients with ≥11 hyperreflective foci was 58.4% at
baseline, falling to 20.8% at 12 months. Further, hyperreflective foci were observed in the outer retinal layers in 50%
of patients at baseline and just 28.6% at 12 months. Mean LogMAR visual acuity improved from 0.55 (95% CI 0.4–0.
71) at baseline to 0.22 (95% CI 0.08–0.35) at 12 months (p < 0.001). Mean central macular thickness decreased from
453.83 μm (95% CI 396.6–511) at baseline to 269.32 μm (95% CI 227.7–310.9) at 12 months (P < 0.001). Central
macular thickness was associated with number (p = 0.017) and distribution (p = 0.004) of hyperreflective foci.
Conclusions: We have observed hyperreflective foci in most of our patients with non-infectious uveitic macular
edema. During follow-up and after treatment, the number of foci diminished and they tended to be located in the
inner layers of the retina.
Keywords: Hyperreflective foci, Intraocular inflammation, Microglia, Optical coherence tomography, Uveitic macular
edema, Uveitis
Background
Macular edema is the main cause of vision loss in pa-
tients with uveitis [1]. Spectral domain optical coherence
tomography (SD-OCT) is the gold standard for the diag-
nosis of this condition. Retinal thickness has come to be
recognized as a remarkably valuable measure in the man-
agement of patients with uveitic macular edema (UME)
and is almost universally used as a main outcome measure
in clinical trials evaluating treatments in uveitis. Qualitative
data provided by SD-OCT, i.e., the presence of subretinal
fluid, distribution of cysts, and ellipsoid zone status, have
also been considered in some papers where the analysis of
these data has contributed to understanding the pathogen-
esis and prognosis of UME [2, 3].
In recent years, hyperreflective foci (HRF) have been de-
scribed in SD-OCT imaging of patients with macular
edema secondary to diabetic retinopathy [4], retinal vein
occlusions [5], type 2 macular telangiectasia [6], and
age-related macular degeneration [7]. Though their origin
* Correspondence: bberasateguif@gmail.com
1Department of Ophthalmology, BioCruces Health Research Institute, Cruces
Hospital, University of the Basque Country, Cruces square s/n, CP 48903
Baracaldo, Vizcaya, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Berasategui et al. BMC Ophthalmology  (2018) 18:179 
https://doi.org/10.1186/s12886-018-0848-5
is not clear, it has been shown that the abundance of such
foci may vary after treatment and has been suggested that
there may be an association between a decrease in HRF
and an improvement in visual function [8, 9]. The aim of
this study was to evaluate the presence and behavior of
HRF in UME. In addition, we assessed the potential asso-




In this multicenter, prospective, observational, 12-month
follow-up study, we included 24 eyes of 24 patients with
UME. Patients were recruited from three referral centers
for ocular inflammatory diseases in Spain (Hospital Clinic
-Barcelona-, Hospital Universitario Cruces -Bilbao- and
Hospital Clinico San Carlos –Madrid-) from january 2014
until september 2014. Local Ethics Committees approved
the study (Comité ético de Investigación Clínica del Hos-
pital Clínic de Barcelona 2013/8574; Comité de ética de la
investigación con medicamentos de Euskadi, Hospital uni-
versitario Cruces PI201406; Comité ético de investigación
clínica del hospital clínico San Carlos de Madrid 13/
244-E). Informed consent was then obtained from each
patient and the research was carried out in accordance
with the Declaration of Helsinki.
Inclusion criteria were age > 18 years, and a diagnosis
of macular edema (defined as central macular thickness
[CMT] of > 300 μm as measured by OCT and fluid in
the macula) secondary to non-infectious uveitis. Exclu-
sion criteria were a diagnosis of infectious uveitis or any
other retinal disease, a history of intraocular surgery in
the last 4 months, and low quality OCT imaging that
precluded adequate assessments.
Type of treatment for macular edema was left to the
discretion of the treating physician.
The Standardization of Uveitis Nomenclature Working
Group criteria were used to anatomically classify the
uveitis [10].
Protocol-based assessments and other study procedures
For the purpose of this study, the following mandatory
protocol-based assessments were performed and are re-
ported in the present study: at baseline, and at 1, 3, 6
and 12 months after treatment. Other visits at different
time-points (i.e., for monitoring pressure or any other
reason) were allowed, at the discretion of the treating
physician.
During each appointment, all patients underwent a full
ophthalmic examination consisting of determination of
best corrected visual acuity (BCVA), which was assessed
with Snellen charts at a test distance of 6 m, anterior seg-
ment biomicroscopy, Goldmann applanation tonometry,
90-D lens biomicroscopy and SD-OCT. Other imaging
methods, e.g., fluorescein angiography, were optional and
were left to the discretion of the researcher. Inflammatory
activity, that is the presence or absence of anterior cham-
ber cells, vitritis or posterior segment inflammatory signs
as judged by the investigator, was recorded at each
protocol-based visit.
SD-OCT
A Cirrus OCT device (version 4.0, Carl Zeiss Meditec,
Dublin, CA) was used in all patients. After pupillary dila-
tation, two scan protocols were performed: the Macular
cube 512 × 128 A-scan, within a 6 × 6 mm2 area centered
on the fovea; and the Enhanced High Definition
Single-Line Raster, which collected data along a 6 mm
horizontal line consisting in 4096 A-scans, across the
center of the fovea. This single line high definition scan
was used to manually count the number of HRF, defined
as discrete, punctiform hyperreflective white lesions (as
hyperreflective as retinal pigment epithelium), and deter-
mine their distribution. As in previous publications [8],
the abundance of HRF was assessed semi-quantitatively,
each case being assigned to one of four groups: group A,
0 foci; group B, 1 to 10; group C, 11 to 20; and group D,
more than 20 foci. Regarding the distribution of HRF,
two locations were considered: the inner retina (IR),
from the nerve fiber layer to the outer plexiform layer;
and the outer retina (OR), from the outer nuclear layer
to retinal pigment epithelium. When HRF were localized
exclusively in the IR, the case was assigned to group 1,
and if there were HRF in the OR (with or without foci in
the IR) the case was assigned to group 2, while cases
with no HRF were assigned to group 0.
All these assessments of the images were performed
by two independent, experienced graders (AF and BB,
from one of the participating centers) who were blind to
clinical data of the corresponding patients. In the event
of discrepancies, the two graders made the assessment
together and reached a consensus.
Statistics
BCVA was converted to the logarithm of the minimum
angle of resolution (logMAR) equivalents for statistical
analyses. Qualitative variables have been described with
percentages or frequencies. Results of logMAR VA and
CMT are shown as estimated means and their 95% con-
fidence intervals (95% CI). Other quantitative variables
have been described using medians and ranges.
The evolution of LogMAR VA and CMT values has
been estimated with a longitudinal lineal model using
Generalized Estimated Equations methodology (GEE).
Estimations of LogMAR VA have been performed un-
adjusted (crude estimation) and adjusted for CMT,
amount of HRF and distribution of HRF in order to assess
a possible influence of these on VA. Estimations of CMT
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have been performed unadjusted (crude estimation) and
adjusted for amount of HRF and distribution of HRF, in
order to assess a possible influence of these on CMT.
GEE models use an unstructured matrix of correla-
tions in order to account for intrasubject variability. All
statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS version 20.0 for
Windows; SPSS Inc., Chicago, IL). P < 0.05 was consid-
ered statistically significant for all analyses.
Results
Baseline characteristics and clinical course
A total of 24 eyes from 24 patients (17 women) were in-
cluded. The median age of the group was 49 years (21–
67). Anatomic diagnosis classified five cases as anterior
uveitis, five as intermediate, eight as posterior and six as
panuveitis. Table 1 displays patients’ demographic data,
causes of uveitis and treatments for macular edema.
The overall logMAR VA improved from 0.55 (0.4–
0.71) at baseline, to 0.42 (0.25–0.59) at 1 month (p =
0.046), 0.42 (0.18–0.66) at 3 months (p = 0.255), 0.31
(0.19–0.42) at 6 months (p = 0.001) and 0.22 (0.08–0.35)
at 12 months (p < 0.001). In parallel, the CMT decreased,
from 453.83 μm (396.6–511) at diagnosis, to 358.34 μm
(301.69–415) at 1 month (p = 0.006), 315.2 μm (258.4–
372.1) at 3 months (p < 0.001), 328.87 μm (262.3–395.5)
at 6 months (p = 0.002) and 269.32 μm (227.7–310.9)
after 1 year (p < 0.001) Fig. 1 shows the evolution of log-
MAR VA and CMT during follow-up. Regarding the
amount of HRF, we observed a progressive reduction in
the percentage of eyes classified as group C or D, that is,
with ≥11 HRF, from 58.4% at baseline, to 40.5% at
1 month, 45.8% at 3 months, 22.7% at 6 months and
21.7% at 12 months. Concerning the distribution of
these foci at baseline, 50% of patients were classified as
group 2 and 50% as group 1 or 0. During follow-up, at
all time points, fewer than half of the patients were clas-
sified as group 2 (that is, patients with HRF in the outer
retina) (month 1, 47.7% in group 2 vs 52.3%in group 0 +
1, month 3: 34.7% vs 65.3%, month 6: 28.6% vs 71.4%,
and month 12: 28.6% vs 71.4%). Grader’s assessments
matched in 111 of 120 scans (92.5%).
Figure 2 shows the number of patients with inflamma-
tory activity at each protocol-based visit.
Table 2 lists logMAR VA and SD-OCT parameters
from all patients during follow-up.
Table 1 Patients’ demographic data, causes of uveitis and treatments for macular edema
Patient Gender Age SUN Cause Treatment
1 Male 34 Anterior HLA-B27 Periocular Triamcinolone
2 Male 40 Anterior HLA-B27 Intravitreal dexamethasone
3 Male 48 Anterior HLA-B27 Oral steroids
4 Male 37 Anterior Idiopathic Oral steroids
5 Female 23 Anterior Idiopathic Oral steroids
6 Female 28 Intermediate Idiopathic Periocular Triamcinolone
7 Female 25 Intermediate Idiopathic Periocular Triamcinolone
8 Female 53 Intermediate Idiopathic Periocular Triamcinolone
9 Female 50 Intermediate Idiopathic Intravitreal dexamethasone
10 Female 35 Intermediate Idiopathic Intravitreal dexamethasone
11 Female 63 Posterior Sarcoidosis Oral steroids + Methotrexate
12 Female 54 Posterior Sarcoidosis Oral steroids + Methotrexate
13 Female 57 Posterior Sarcoidosis Oral steroids + Adalimumab
14 Female 61 Posterior Sarcoidosis Oral steroids + Adalimumab
15 Male 61 Posterior Birdshot Oral steroids + Tocilizumab
16 Male 34 Posterior Birdshot Oral steroids + Cyclosporine
17 Female 59 Posterior Idiopathic Oral steroids
18 Female 50 Posterior Idiopathic Oral steroids
19 Female 67 Panuveitis Sarcoidosis Oral steroids + Adalimumab
20 Female 21 Panuveitis Sarcoidosis Oral steroids + Adalimumab
21 Female 35 Panuveitis Chronic VKH Oral steroids + Azathioprine
22 Female 47 Panuveitis Chronic VKH Periocular triamcinolone+Azathioprine
23 Female 61 Panuveitis Idiopathic Oral steroids
24 Male 53 Panuveitis Idiopathic Oral steroids
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Tables 3, 4, 5 and 6 show logMAR VA and HRF re-
lated data in patients with anterior, intermediate, poster-
ior and panuveitis respectively.
Influence of OCT parameters on visual acuity
The adjusted model for the estimation of VA showed
that the decrease in CMT was associated with the in-
crease in VA (p = 0.002). However VA was not associated
with either HRF number or distribution (p = 0.513 and
p = 0.324 respectively). On the other hand, the adjusted
model for the estimation of CMT showed that both HRF
number (p = 0.017) and distribution (p = 0.004) had an
influence on CMT values, that is, the decrease in CMT
was associated with a decrease in the number of HRF
and the distribution of the foci.
Discussion
In this prospective study we describe, to our knowledge
for the first time, the behavior of HRF in patients with
UME. At baseline, patients had larger numbers of foci
and half of them had at least some foci in the outer ret-
ina. During follow-up, while macular edema resolved,
OCT showed fewer foci and those that remained were
more frequently located in the inner retina. Figure 3 il-
lustrates this behavior. Moreover, macular thickness was
found to be associated with both the number and the
distribution of the foci.
Although HRF have been described in several diseases
including diabetic macular edema, age-related macular
degeneration, retinal vein occlusions and type 2 macular
telangiectasia, the precise nature of these foci and their
Fig. 1 Evolution of logMAR visual acuity (solid line) and central macular thickness (CMT, dashed line) during follow-up
Fig. 2 Number of patients with inflammatory activity at each protocol-based visit
Berasategui et al. BMC Ophthalmology  (2018) 18:179 Page 4 of 9
molecular constituents remain unclear. Three main the-
ories have been put forward in publications concerning
these foci. Some authors have hypothesized that HRF
represent precursors of hard exudates [4, 11]. Others
suggested that they are degenerated photoreceptors or
macrophages engulfing such cells, since they have been
observed close to disrupted external limiting membrane
and ellipsoid zone and have been associated with de-
creased VA [12]. Finally, other authors have interpreted
them as microglial cells activated during an inflamma-
tory reaction [13, 14]. All these theories are plausible
and it is possible that all three mechanisms may occur
in the same disease but it is likely that each one of them
plays a predominant role in a given disease.
Shape of foci is described as round or oval in previous
publications regarding HRF in patients with retinal vas-
cular diseases. Our cases showed also round or oval foci.
Regarding the size, hyperreflective foci are defined as
“small” in publications that evaluate this feature in pa-
tients with retinal vascular diseases, though precise size
is not reported. In SD-OCT figures provided in these
publications displaying foci, variable sizes may be ob-
served. Though it is a subjective judgement, we believe
that in our uveitic patients, foci are usually smaller than
those observed in patients with diabetic macular edema
or retinal vein occlusions. We speculate that this may be
explained by a different origin of foci in different dis-
eases. In retinal vascular diseases bigger foci may corres-
pond to lipid exudation; on the other hand smaller foci
seen in our patients may correspond to inflammatory
cells. A microglial and leukocytic origin of the HRF
would seem the most plausible in the context of UME,
given the clear inflammatory origin of this condition,
and the absence of hard exudates in UME. This may
support the view that HRF should not be considered an
initial lipidic extravasation in these cases. In this regard,
a study assessing SD-OCT imaging of the vitreous and
retina of seven patients with posterior segment inflam-
matory disease described HRF of a size consistent with
that expected for inflammatory cells [15]. Interestingly,
data from studies performed in murine experimental
autoimmune uveoretinitis assessing correlations of OCT
imaging of inflammatory lesions and their histopatho-
logic analysis have shown that HRF may represent cellu-
lar infiltration [16].
In our patients, HRF decreased over time after starting
treatment, whilst macular thickness decreased and edema
resolved. Similar findings have been described by other re-
searchers in patients with retinal vasculopathies and
age-related macular degeneration. In diabetic macular
edema, Vujosevic et al. [9] assessed the presence of HRF
and the effect of treatment with anti-vascular endothelial
growth factor on their abundance. They observed that the
number of foci decreased after treatment, but did not find
a correlation between the number of HRF and retinal
thickness. In patients with macular edema secondary to
diabetic retinopathy or branch retinal vein occlusions
treated with intravitreal implant of dexamethasone or
Table 2 Changes in SD-OCT parameters and visual acuity over follow-up (all patients)
Baseline Month 1 Month 3 Month 6 Month 12
Frequency of patients with ≥11
foci(groups C or D)
58.3% 40.5% 45.8% 22.7% 21.7%
Distribution (% patients in each group)
Group 0 (no foci) 4.2% 4.8% 8.7% 14.3% 4.7%
Group 1 (inner retina) 45.8% 47.5% 56.6% 57.1% 66.7%
Group 2 (outer retina) 50% 47.7% 34.7% 28.6% 28.6%
logMAR VAa 0.55 (0.4–0.71) 0.42 (0.25–0.59) 0.42 (0.18–0.66) 0.31 (0.19–0.42) 0.22 (0.08–0.35)
CMT (μm)b 453.83 (396.6–511) 358.34 (301.69–415) 315.2 (258.4–372.1) 328.87 (262.3–395.5) 269.32 (227.7–310.9)
alogMAR VA: logarithm of the minimum angle of resolution visual acuity
bCMT: Central macular thickness
Table 3 Behavior of foci and evolution of visual acuity in patients with anterior uveitis
Baseline Month 1 Month 3 Month 6 Month 12
Frequency of patients with ≥11 foci(groups C or D) 40% 40% 40% 0% 0%
Distribution (% patients in each group)
Group 0 (no foci) 20% 20% 40% 0% 0%
Group 1 (inner retina) 20% 40% 40% 100% 75%
Group 2 (outer retina) 60% 40% 20% 0% 25%
Mean logMAR VAa 0.56 0.32 0.32 0.2 0.125
alogMAR VA: logarithm of the minimum angle of resolution visual acuity
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ranibizumab, Chatziralli et al. observed a decrease in HRF
in parallel with resolution of the macular edema [17].
Framme et al. described a reduction in the number of
HRF in 54% of their patients with neovascular choroidal
neovascularization after treatment with ranibizumab [7].
Moreover, this reduction correlated with a decrease in
CMT. Abri Aghdam et al. assessed the behavior of HRF in
patients with neovascular age related macular degener-
ation after treatment with intravitreal aflibercept [18].
They observed a decrease in the number of foci within ra-
dius of 500 and 1500 μm, as well as a correlation between
the CMT and number of foci within a 500-μm radius. To
explain this behavior, these researchers suggested that
HRF were precursors of lipid exudates and hence a sign of
hyperpermeability, which might explain the association
found between number of foci and macular thickness.
In patients with UME, the inflammatory process in-
duces the invasion of leukocytes into the retina and the
activation of microglia. These undergo significant
changes in shape and size, from ramified multidirec-
tional extensions to polarized dendrites and then to lar-
ger rounded cells which aggregate [19]. Leukocytes and
activated microglial cells produce cytokines that increase
vascular and epithelial permeability. When the inflam-
mation resolves, the level of retinal cellular infiltrates de-
creases. These phenomena may support our finding of
an association between HRF number and macular
thickness.
As mentioned above, almost half of our cases showed
HRF in the outer retina at baseline. During follow-up, as
the edema resolved, foci were more frequently located in
the inner retina. Similar observations have been described
in diabetic macular edema. Vujosevic et al. [9], in their
study assessing the effect of ranibizumab on HRF in dia-
betic macular edema, reported that the main decrease in
foci occurred in the outer nuclear layer when edema re-
solved. Zheng et al. [19] showed that resting microglia are
physiologically located in the inner retinal layers in human
eyes. In the same study it was shown that activated micro-
glia migrate towards the outer retinal layers in human eyes
with diabetic macular edema and it is suggested that pro-
inflammatory cytokines are responsible for the activation
of microglia. Interestingly, in a rat model of experimental
autoimmune uveoretinitis, Rao et al. showed that micro-
glia had migrated from the nerve fiber layer and other
inner retinal layers to the photoreceptor layer at day 9
after the induction of uveitis [20]. Moreover, Ding X et al.
showed that rat microglial cells activated by lipopolysac-
charides secreted proinflammatory cytokines (tumour ne-
crosis factor and interleukin beta) which could promote
vascular dysfunction and hence permeability [21]. These
findings could explain the high frequency of patients with
HRF in the outer retina at baseline, when macular edema
was present and hence the inflammatory process was ac-
tive. It has been shown that glucocorticoids inhibit micro-
glial migration [22]. We speculate that the treatment
given in our patients (mainly glucocorticoids) may explain
the behavior of the HRF after treatment, that is, a more
frequent location of foci in the inner retina.
We have not found the number or location of the
HRF to have an independent influence on VA. Previous
studies have evaluated possible associations between
HRF and visual outcomes in diabetic macular edema,
retinal vein occlusions and neovascular age-related
Table 4 Behavior of foci and evolution of visual acuity in patients with intermediate uveitis
Baseline Month 1 Month 3 Month 6 Month 12
Frequency of patients with ≥11 foci(groups C or D) 60% 20% 60% 20% 20%
Distribution (% patients in each group)
Group 0 (no foci) 0% 0% 0% 0% 25%
Group 1 (inner retina) 40% 100% 80% 100% 50%
Group 2 (outer retina) 60% 0% 20% 0% 25%
Mean logMAR VAa 0.28 0.25 0.23 0.24 0.21
a logMAR VA: logarithm of the minimum angle of resolution visual acuity
Table 5 Behavior of foci and evolution of visual acuity in patients with posterior uveitis
Baseline Month 1 Month 3 Month 6 Month 12
Frequency of patients with ≥11 foci(groups C or D) 62.5% 28.5% 25% 14.2% 12.5%
Distribution (% patients in each group)
Group 0 (no foci) 0% 0% 0% 0% 0%
Group 1 (inner retina) 50% 28.5% 57% 62.5% 85.7%
Group 2 (outer retina) 50% 71.5% 43% 37.5% 14.3%
Mean logMAR VAa 0.5 0.3 0.41 0.25 0.18
a logMAR VA: logarithm of the minimum angle of resolution visual acuity
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macular degeneration. In the study by Vujosevic et al.,
the number of foci was correlated inversely with retinal
sensitivity and directly with non-stable fixation, as mea-
sured by microperimetry [9]. Uji et al. found an associ-
ation between the presence of HRF in the outer retinal
layers and poor VA in patients with diabetic macular
edema [12]. Moreover, both HRF and VA were associ-
ated with disruptions in the external limiting membrane
and in the junction between the inner and outer seg-
ment of the photoreceptors (nowadays known as the el-
lipsoid zone). In the study by Chatziralli et al. performed
in patients with diabetic macular edema and retinal vein
occlusions, a higher number of HRF was associated with
poorer VA [17]. Kang et al. found that the number of
HRF at baseline was inversely associated with final VA
in patients with diabetic macular edema treated with
Table 6 Behavior of foci and evolution of visual acuity in patients with panuveitis uveitis
Baseline Month 1 Month 3 Month 6 Month 12
Frequency of patients with ≥11 foci(groups C or D) 66.7% 80% 66.7% 60% 60%
Distribution (% patients in each group)
Group 0 (no foci) 0% 0% 0% 16.7% 0%
Group 1 (inner retina) 67% 40% 50% 33.3% 50%
Group 2 (outer retina) 33% 60% 50% 50% 50%
Mean logMAR VAa 0.85 0.8 0.69 0.55 0.40




Fig. 3 Example of behavior of HRF number and distribution as detected by SD-OCT over the course of follow-up. Circles highlight foci. Left eye
of a 61-year-old man with chronic idiopathic anterior uveitis. a At baseline, multiple HRF scattered across all retina layers and macular edema
(assigned to groups D and 2. b At 6 months, HRF number reduced and outer retina not affected (assigned to groups B and 1). c At 12 months,
no visible foci (assigned to groups A and 0)
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intravitreal bevacizumab [23]. The same group reported
similar findings in patients with branch retinal vein occlu-
sion [8], neovascular age-related macular degeneration
and polypoidal choroidal neovascular vasculopathy [24].
In most of the aforementioned studies, HRF are as-
sumed to be extravasations of lipoproteins and precur-
sors of lipid exudates and the researchers consistently
suggest that the underlying pathogenesis of poorer visual
outcomes may be related to a toxic effect of lipids on
photoreceptors. Regarding UME, it has been shown in a
rat model of experimental autoimmune uveoretinitis that
activated microglia located at the photoreceptor layer se-
crete peroxynitrite, which is the most potent biological
oxidant known and capable of oxidizing cellular compo-
nents [20]. Assuming a microglial origin of the foci, one
could expect some deleterious effect on photoreceptors
and hence on VA, due to the presence of microglia in
the outer retina. We failed, however, to demonstrate an
association between BCVA and HRF number or distribu-
tion. A protective effect of the treatment administered,
usually local or systemic steroids, on photoreceptors and/
or an insufficient capability of the BCVA test to highlight
functional damage may explain this finding.
The main limitation of our study is the subjective as-
sessment and counting of HRF. Nevertheless, agreement
between graders of the scans was high. In the future,
software able to automatically measure the amount of
HRF may help us objectively define the behavior of such
foci and clarify their meaning and relevance. Other limi-
tations are the relatively small size of the sample and
that the SD-OCT device used lacks software capable of
performing consecutive scans in the same retinal sec-
tion. Strengths of our study are its prospective nature
and the long-term follow-up.
Conclusions
In conclusion, SD-OCT scans showed HRF in eyes with
UME in our study. After treatment, the number of foci
decreased and their distribution changed, remaining foci
locating preferentially in the inner retina, and this was
associated with a decrease in macular thickness. Further
studies with larger numbers of patients are needed to
confirm these results and shed light on their implica-
tions for clinical practice.
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